Monotherapy with docetaxel in second- or third-line treatment of anthracycline-resistant metastatic breast cancer

Anti-Cancer Drugs

Volumn 11, Issue 3, 2000, Pages 149-153

  Brodowicz, Thomas ^a   Koestler, Wolfgang J ^a   Tomek, Sandra ^a   Vaclavik, Ilse ^a   Herscovici, Vinia ^a   Wiltschke, Christoph ^a   Steger, Günther G ^a   Zielinski, Christoph C ^a,b,c  

^a UNIVERSITY HOSPITAL INNSBRUCK   (Austria)

^b LUDWIG BOLTZMANN INSTITUTE FOR LUNG VASCULAR RESEARCH   (Austria)

^c UNIVERSITY OF VIENNA   (Austria)

Author keywords

Chemotherapy; Docetaxel; Metastatic breast cancer

Indexed keywords

ANTHRACYCLINE; DOCETAXEL; GEMCITABINE; TAXANE DERIVATIVE;

ADULT; AGED; ANEMIA; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; LEUKOPENIA; METASTASIS; NAIL DISEASE; NEUROTOXICITY; ONYCHOLYSIS; POLYNEUROPATHY; PRIORITY JOURNAL; THROMBOCYTOPENIA;

ADULT; ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, PHYTOGENIC; AUSTRIA; BREAST NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; NEOPLASM METASTASIS; PACLITAXEL; SALVAGE THERAPY; SURVIVAL ANALYSIS; TAXOIDS; TREATMENT OUTCOME;

EID: 0034059279     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200003000-00002     Document Type: Article

References (24)

1. 1. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996; 14: 2197-205.
2. 2. Brodowicz T, Wiltschke C, Hejna M, Zielinski CC. Fortschritte in der Hormontherapie des Mammakarzinoms. Onkologie 1998; 21: 429-33.
3. 3. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998; 339: 974-84.
4. 4. Gianni AM, Siena S, Bregni M, et al. Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results. J Clin Oncol 1997; 15: 2312-21.
5. 5. Bezwoda WR, Seymour L, Dansey RD. High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 1995; 13: 2483-9.
6. 6. Stadtmauer EA, O'Neill A, Goldstein LJ, et al. Phase III randomized trial of high-dose chemotherapy and stem cell support shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate and 5-fluorouracil for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the 'Philadelphia' intergroup study (BPT-1). Proc Am Soc Clin Oncol 1999; 18: 1 (abstr 1).
7. 7. Bezwoda WR. Randomized, controlled trial of high dose chemotherapy vs. standard dose chemotherapy for high risk, surgically treated, primary breast cancer. Proc Am Soc Clin Oncol 1999; 18: 2 (abstr 4).
8. 8. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/ neu-overexpressing metastatic breast cancer. J Clin Oncol 1996; 14: 737-44.
9. 9. Cobleigh MA, Vogel CL, Tripathy D, et al. Efficacy and safety of herceptin (humanized anti-Her2 antibody) as a single agent in 222 women with Her2 overexpression who relapsed following chemotherapy for metastatic breast cancer. Proc Am Soc Clin Oncol 1998; 17: 97 (abstr 376).
10. 10. Slamon D, Leyland-Jones B, Shak S, et al. Addition of herceptin (humanized anti-Her2 antibody) to first line chemotherapy for Her2 overexpressing metastatic breast cancer markedly increases anticancer activity: a randomized, multinational controlled phase III trial. Proc Am Soc Clin Oncol 1998; 17: 98 (abstr 377).
11. 11. Fornier M, Seidman AD, Esteva FJ, et al. Weekly herceptin +1 hour taxol: phase II study in Her2 overexpressing and non-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 126 (abstr 482).
12. 12. Norton L, Slamon D, Leyland-Jones B, et al. Overall survival advantage to simultaneous chemotherapy plus the humanized anti-Her2 monoclonal antibody herceptin in Her2-overexpressing metastatic breast cancer. Proc Am Soc Clin Oncol 1999; 18: 127 (abstr 483).
13. 13. Holmes FA, Walters RS, Theriault RL, et al. Phase II trial of taxol, an active drug in the treatment of metastatic breast cancer. J Natl Cancer Inst 1991; 83: 1797-805.
14. 14. Trudeau ME, Eisenhauer EA, Higgins BP, et al. Docetaxel in patients with metastatic breast cancer: a phase II study of the National Cancer Institute of Canada - Clinical Trials Group. J Clin Oncol 1996; 14: 422-8.
15. 15. Chan S, Friedrichs K, Noel D, et al. A randomized phase III study of taxotere versus doxorubicin in patients with metastatic breast cancer who have failed an alkylating containing regimen: preliminary results. Proc Am Soc Clin Oncol 1997; 16: 154 (abstr 540).
16. 16. Ravdin PM, Burris HA, Cook G, et al. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer. J Clin Oncol 1995; 13: 2879-85.
17. 17. Valero V, Holmes FA, Walters RS, et al. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer. J Clin Oncol 1995; 13: 2886-94.
18. 18. Nabholtz JM, Senn HJ, Bezwoda WR, et al. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. J Clin Oncol 1999; 17: 1413-24.
19. 19. Gueritte-Voegelein F, Guenard D, Lavelle F, Le-Goff MT, Mangatal L, Potier P. Relationships between the structure of taxol analogues and their antimitotic activity. J Med Chem 1991; 34: 992-8.
20. 20. Aapro M, Goldhirsch A. New paradigms in the treatment of advanced breast cancer. Semin Oncol 1998; 25: 1-2.
21. 2 as first-line chemotherapy for patients with advanced breast cancer: report of the Clinical Screening Group of the EORTC. Br J Cancer 1996; 74: 650-6.
22. 22. Chevallier B, Fumoleau P, Kerbrat P, et al. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1995; 13: 314-22.
23. 23. Van Oosterom AT. Docetaxel (Taxotere): an effective agent in the management of second-line breast cancer. Semin Oncol 1995; 22 (suppl 13): 22-8.
24. 24. Nabholtz JM. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer. Semin Oncol 1999; 26 (3 suppl 9): 7-13.